How should we determine length of anticoagulation after proximal deep vein thrombosis of the lower limbs?

British Journal of Haematology

Volumn 144, Issue 6, 2009, Pages 832-837

  Siragusa, Sergio ^a,b   Caramazza, Domenica ^b   Malato, Alessandra ^b  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

Anticoagulation; Deep vein thrombosis; Duration

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; D DIMER; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANTICOAGULATION; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG WITHDRAWAL; HUMAN; LEG THROMBOSIS; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; THROMBOPHILIA; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

BIOLOGICAL MARKERS; DRUG ADMINISTRATION SCHEDULE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYTIC AGENTS; HUMANS; NEOPLASMS; RECURRENCE; RISK ASSESSMENT; TIME FACTORS; VENOUS THROMBOSIS; VITAMIN K; VITAMINS;

EID: 60649108493     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07578.x     Document Type: Review

References (41)

1. Agnelli, G., Prandoni, P., Santamaria, M.G., Bagatella, P., Iorio, A., Bazzan, M., Moia, M., Guazzaloca, G., Bertoldi, A., Tomasi, C., Scannapieco, G. Ageno, W. Warfarin Optimal Duration Italian Trial Investigators. (2001) Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. New England Journal of Medicine, 345, 165 169.
2. Agnelli, G., Prandoni, P., Becattini, C., Silingardi, M., Taliani, M.R., Miccio, M., Imberti, D., Poggio, R., Ageno, W., Pogliani, E., Porro, F. Zonzin, P. Warfarin Optimal Duration Italian Trial Investigators. (2003) Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Annals of Internal Medicine, 139, 19 25.
3. Baglin, T., Luddington, R., Brown, K. Baglin, C. (2003) Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet, 362, 523 526.
4. Baglin, T., Luddington, R., Brown, K. Baglin, C. (2004) High risk of recurrent venous thromboembolism in men. Journal of Thrombosis and Haemostasis, 2, 2152 2155.
5. Baglin, T., Palmer, C.R., Luddington, R. Baglin, C. (2008) Unprovoked recurrent venous thrombosis: prediction by D-dimer and clinical risk factors. Journal of Thrombosis and Haemostasis, 6, 577 582.
6. Campbell, I.A., Bentley, D.P., Prescott, R.J., Routledge, P.A., Shetty, H.G.M. Williamson, I.J. (2007) Anticoagulation for three versus six months in patients with deep-vein thrombosis or pulmonary embolism, or both, randomized trial. British Medical Journal, 334, 674.
7. Christiansen, S., Cannegieter, S., Koster, T., Vanderbroucke, J. Rosendaal, F. (2005) Thrombophilia, clinical factors, and recurrent venous thrombotic events. Journal of American Medical Association, 293, 2352 2361.
8. Cosmi, B., Legnani, C., Cini, M., Guazzaloca, G. Palareti, G. (2005) D-dimer levels in combination with residual venous obstruction and the risk of recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis. Thrombosis and Haemostasis, 94, 969 974.
9. Heit, J., Silverstein, M., Mohr, D., Petterson, T., O'Fallon, W. Melton, III., L. (2000) Risk factors for deep vein thrombosis and pulmonary embolism. Archives of Internal Medicine, 160, 80915.
10. Ho, W.K., Hankey, G.J., Quinlan, D.J. Eikelboom, J.W. (2006) Risk of recurrent venous thromboembolism in patients with common thrombophilia. A systematic review. Archives of Internal Medicine, 166, 729 736.
11. Hull, R.D., Pineo, G.F., Brant, R.F., Mah, A.F., Burke, N., Dear, R., Wong, T., Cook, R., Solymoss, S., Poon, M.C. Raskob, G. LITE Trial Investigators. (2006) Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. American Journal of Medicine, 119, 1062 1072.
12. Kearon, C., Gent, M., Hirsh, J., Weitz, J., Kovacs, M.J., Anderson, D.R., Turpie, A.G., Green, D., Ginsberg, J.S., Wells, P., MacKinnon, B. Julian, J.A. (1999) A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. New England Journal of Medicine, 340, 901 907.
13. Kearon, C., Ginsberg, J.S., Kovacs, M.J., Anderson, D.R., Wells, P., Julian, J.A., MacKinnon, B., Weitz, J.I., Crowther, M.A., Dolan, S., Turpie, A.G., Geerts, W., Solymoss, S., van Nguyen, P., Demers, C., Kahn, S.R., Kassis, J., Rodger, M., Hambleton, J. Gent, M. Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators. (2003) Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. New England Journal of Medicine, 349, 631 639.
14. Kearon, C., Ginsberg, J.S., Anderson, D.R., Kovacs, M.J., Wells, P., Julian, J.A., Mackinnon, B., Demers, C., Douketis, J., Turpie, A.G., Van Nguyen, P., Green, D., Kassis, J., Kahn, S.R., Solymoss, S., Desjardins, L., Geerts, W., Johnston, M., Weitz, J.I., Hirsh, J. Gent, M. SOFAST Investigators. (2004) Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. Journal of Thrombosis and Haemostasis, 2, 743 749.
15. Kearon, C., Kahn, S.R., Agnelli, G., Goldhaber, S., Raskob, G.E. Comerota, A.J. American College of Chest Physicians. (2008a) Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest, 133, 454S 545S.
16. Kearon, C., Julian, J.A., Kovacs, M.J., Anderson, D.R., Wells, P., Mackinnon, B., Weitz, J.I., Crowther, M.A., Dolan, S., Turpie, A.G., Geerts, W., Solymoss, S., van Nguyen, P., Demers, C., Kahn, S.R., Kassis, J., Rodger, M., Hambleton, J., Gent, M. Ginsberg, J.S. (2008b) Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood, 112, 4432 4436.
17. Kyrle, P.A., Minar, E., Bialonczyk, C., Hirschl, M., Weltermann, A. Eichinger, S. (2004) The risk of recurrent venous thromboembolism in men and women. New England Journal of Medicine, 350, 2558 2563.
18. Lee, A.Y., Levine, M.N., Baker, R.I., Bowden, C., Kakkar, A.K., Prins, M., Rickles, F.R., Julian, J.A., Haley, S., Kovacs, M.J. Gent, M. Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. (2003) Low-molecular weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. New England Journal of Medicine, 349, 146 153.
19. Levine, M.N., Hirsh, J., Gent, M., Turpie, A.G., Weitz, J., Ginsberg, J., Geerts, W., LeClerc, J., Neemeh, J. Powers, P. (1995) Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thrombosis and Haemostasis, 74, 606 611.
20. Linkins, L., Choi, P.T. Douketis, J.D. (2003) Clinical impact of bleeding in patients taking oral anticoagulant therapy for with venous thromboembolism: a meta-analysis. Annals of Internal Medicine, 139, 893 900.
21. Marchiori, A., Mosena, L., Prins, M.H. Prandoni, P. (2007) The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. Haematologica, 92, 1107 1114.
22. McRae, S., Tran, H., Schulman, S., Ginsberg, J. Kearon, C. (2006) Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet, 368, 371 378.
23. Ost, G., Tepper, J., Mihara, H., Lander, O., Heinzer, R. Fein, A. (2005) Duration of anticoagulation after venous thromboembolism. A meta-analysis. Journal of American Medical Association, 294, 706 715.
24. Palareti, G., Legnani, C., Cosmi, B., Guazzaloca, G., Pancani, C. Coccheri, S. (2002) Risk of venous thromboembolism recurrence: high negative predictive value of d-dimer performed after oral anticoagulation is stopped. Thrombosis and Haemostasis, 87, 7 12.
25. Palareti, G., Cosmi, B., Legnani, C., Tosetto, A., Brusi, C., Iorio, A., Pengo, V., Ghirarduzzi, A., Pattacini, C., Testa, S., Lensing, A.W. Tripodi, A. PROLONG Investigators. (2006) D-dimer testing to determine the duration of anticoagulation therapy. New England Journal of Medicine, 355, 1780 1789.
26. Pinede, L., Ninet, J., Duhaut, P., Chabaud, S., Demolombe-Rague, S., Durieu, I., Nony, P., Sanson, C. Boissel, J.P. Investigators of the 'Durée Optimale du Traitement AntiVitamines K' (DOTAVK) Study. (2001) Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation, 103, 2453 2460.
27. Piovella, F., Crippa, L., Barone, M., Viganò D'Angelo, S., Serafini, S., Galli, L., Beltrametti, C. D'Angelo, A. (2002) Normalization rates of compression ultrasonography in patients with a first episode of deep vein thrombosis of the lower limbs: association with recurrence and new thrombosis. Haematologica, 87, 515 522.
28. Prandoni, P., Lensing, A.W., Cogo, A., Cuppini, S., Villalta, S., Carta, M., Cattelan, A.M., Polistena, P., Bernardi, E. Prins, M.H. (1996) The long-term clinical course of acute deep venous thrombosis. Annals of Internal Medicine, 125, 1 7.
29. Prandoni, P., Lensing, A.W., Prins, M.H., Bernardi, E., Marchiori, A., Bagatella, P., Frulla, M., Mosena, L., Tormene, D., Piccioli, A., Simioni, P. Girolami, A. (2002a) Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Annals of Internal Medicine, 137, 955 960.
30. Prandoni, P., Lensing, A.W., Piccioli, A., Bernardi, E., Simioni, P., Girolami, B., Marchiori, A., Sabbion, P., Prins, M.H., Noventa, F. Girolami, A. (2002b) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood, 100, 3484 3488.
31. Prandoni, P., Lensing, A.W.A., Prins, M., Ghirarduzzi, A., Ageno, W., Imberti, D., Villalta, S., Parisi, R., Pesavento, R., Cuppini, S., Quintavalla, R. Agnelli, G. (2007) Prevention of recurrent thromboembolism by adjusting the duration of anticoagulation according to residual vein thrombosis. A randomized study. Journal of Thrombosis and Haemostasis, 5 (suppl. 1 Abs 056.
32. Research Committee of the British Thoracic Society. (1992) Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet, 340, 873 876.
33. Ridker, P.M., Goldhaber, S.Z., Danielson, E., Rosenberg, Y., Eby, C.S., Deitcher, S.R., Cushman, M., Moll, S., Kessler, C.M., Elliott, C.G., Paulson, R., Wong, T., Bauer, K.A., Schwartz, B.A., Miletich, J.P., Bounameaux, H. Glynn, R.J. PREVENT Investigators. (2003) Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. New England Journal of Medicine, 348, 1425 1434.
34. Schulman, S., Rhedin, A.S., Lindmarker, P., Carlsson, A., Lärfars, G., Nicol, P., Loogna, E., Svensson, E., Ljungberg, B. Walter, H. (1995) A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. New England Journal of Medicine, 332, 1661 1665.
35. Schulman, S., Granqvist, S., Holmström, M., Carlsson, A., Lindmarker, P., Nicol, P., Eklund, S.G., Nordlander, S., Lärfars, G., Leijd, B., Linder, O. Loogna, E. (1997) The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. New England Journal of Medicine, 336, 393 398.
36. Schulman, S., Lindmarker, P., Holmström, M., Lärfars, G., Carlsson, A., Nicol, P., Svensson, E., Ljungberg, B., Viering, S., Nordlander, S., Leijd, B., Jahed, K., Hjorth, M., Linder, O. Beckman, M. (2006) Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. Journal of Thrombosis and Haemostasis, 4, 734 742.
37. Segal, J.B., Streiff, M.B., Hofmann, L.V., Thornton, K. Bass, E.B. (2007) Management of venous thromboembolism: a systematic review for a practice guideline. Annals of Internal Medicine, 146, 211 222.
38. Siragusa, S. (2008) Residual vein thrombosis for assessing the optimal management of deep vein thrombosis in cancer patients: an interim analysis of the cancer DACUS study. Blood, 112, 985a.
39. Siragusa, S., Malato, A., Bellisi, M., Attanzio, M.T., Cigna, V., Caramazza, D., Lo Coco, L.L., Milio, G. Bajardi, G. (2007) Absence of residual vein thrombosis after an episode of idiopathic deep vein thrombosis: short-term anticoagulation is safe. The "Extended Dacus Study". Blood, 110, 301a.
40. Siragusa, S., Malato, A., Anastasio, R., Cigna, V., Milio, G., Amato, C., Bellisi, M., Attanzio, M.T., Cormaci, O., Pellegrino, M., Dolce, A., Casuccio, A., Bajardi, G. Mariani, G. (2008) Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the duration of anticoagulation based on compression ultrasonography (DACUS) study. Blood, 112, 511 515.
41. Van Dongen, C., Vink, R., Hutten, B., Buller, H. Prins, M. (2003) The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event. Archives of Internal Medicine, 163, 1285 1293.